RU2743188C2 - Химерные антигенные рецепторы к каппа-антигену миеломы и варианты их применения - Google Patents

Химерные антигенные рецепторы к каппа-антигену миеломы и варианты их применения Download PDF

Info

Publication number
RU2743188C2
RU2743188C2 RU2017138528A RU2017138528A RU2743188C2 RU 2743188 C2 RU2743188 C2 RU 2743188C2 RU 2017138528 A RU2017138528 A RU 2017138528A RU 2017138528 A RU2017138528 A RU 2017138528A RU 2743188 C2 RU2743188 C2 RU 2743188C2
Authority
RU
Russia
Prior art keywords
ser
domain
car
leu
gly
Prior art date
Application number
RU2017138528A
Other languages
English (en)
Russian (ru)
Other versions
RU2017138528A3 (OSRAM
RU2017138528A (ru
Inventor
Кеннет МИКЛТУЭЙТ
Розан ДАНН
Дэвид ГОТТЛИБ
Грант ЛОГАН
Original Assignee
Хемалоджикс Пти. Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Хемалоджикс Пти. Лтд. filed Critical Хемалоджикс Пти. Лтд.
Publication of RU2017138528A publication Critical patent/RU2017138528A/ru
Publication of RU2017138528A3 publication Critical patent/RU2017138528A3/ru
Application granted granted Critical
Publication of RU2743188C2 publication Critical patent/RU2743188C2/ru

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503Immunoglobulin superfamily
    • C07K14/7051T-cell receptor (TcR)-CD3 complex
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/20Interleukins [IL]
    • A61K38/204IL-6
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00Cellular immunotherapy
    • A61K40/10Cellular immunotherapy characterised by the cell type used
    • A61K40/11T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00Cellular immunotherapy
    • A61K40/30Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31Chimeric antigen receptors [CAR]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00Cellular immunotherapy
    • A61K40/40Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41Vertebrate antigens
    • A61K40/42Cancer antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/54Interleukins [IL]
    • C07K14/5412IL-6
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/54Interleukins [IL]
    • C07K14/5434IL-12
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503Immunoglobulin superfamily
    • C07K14/70521CD28, CD152
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0634Cells from the blood or the immune system
    • C12N5/0636T lymphocytes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52Constant or Fc region; Isotype
    • C07K2317/526CH3 domain
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52Constant or Fc region; Isotype
    • C07K2317/53Hinge
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/01Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/01Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/035Fusion polypeptide containing a localisation/targetting motif containing a signal for targeting to the external surface of a cell, e.g. to the outer membrane of Gram negative bacteria, GPI- anchored eukaryote proteins
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
RU2017138528A 2015-04-23 2016-04-25 Химерные антигенные рецепторы к каппа-антигену миеломы и варианты их применения RU2743188C2 (ru)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562151968P 2015-04-23 2015-04-23
US62/151,968 2015-04-23
US201562158407P 2015-05-07 2015-05-07
US62/158,407 2015-05-07
PCT/US2016/029203 WO2016172703A2 (en) 2015-04-23 2016-04-25 Kappa myeloma antigen chimeric antigen receptors and uses thereof

Publications (3)

Publication Number Publication Date
RU2017138528A RU2017138528A (ru) 2019-05-07
RU2017138528A3 RU2017138528A3 (OSRAM) 2019-09-03
RU2743188C2 true RU2743188C2 (ru) 2021-02-16

Family

ID=57143653

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2017138528A RU2743188C2 (ru) 2015-04-23 2016-04-25 Химерные антигенные рецепторы к каппа-антигену миеломы и варианты их применения

Country Status (18)

Country Link
US (2) US11305011B2 (OSRAM)
EP (2) EP4368641A3 (OSRAM)
JP (3) JP7229768B2 (OSRAM)
KR (1) KR102623427B1 (OSRAM)
CN (1) CN107922489B (OSRAM)
AU (1) AU2016253126B2 (OSRAM)
BR (1) BR112017022838A2 (OSRAM)
CA (1) CA2978964A1 (OSRAM)
DK (1) DK3286223T5 (OSRAM)
ES (1) ES2976236T3 (OSRAM)
FI (1) FI3286223T3 (OSRAM)
HK (1) HK1252854A1 (OSRAM)
HR (1) HRP20240415T1 (OSRAM)
HU (1) HUE065799T2 (OSRAM)
IL (1) IL255207B2 (OSRAM)
PT (1) PT3286223T (OSRAM)
RU (1) RU2743188C2 (OSRAM)
WO (1) WO2016172703A2 (OSRAM)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3286223T (pt) 2015-04-23 2024-03-22 HaemaLogiX Ltd Recetores de antigénio quimérico do antigénio do mieloma kappa e suas utilizações
CN107529550A (zh) * 2017-08-28 2018-01-02 马晓冬 一种基于PiggyBac载体的CD‑19‑CAR‑T系统构建方法
US20200261502A1 (en) * 2017-09-08 2020-08-20 Carsgen Therapeutics Co., Ltd. Genetically engineered t cell and application thereof
WO2019108932A1 (en) * 2017-11-30 2019-06-06 Haemalogix Pty. Ltd. Methods for expanding kappa myeloma antigen chimeric antigen receptors expressing cells
CN112189018A (zh) * 2018-04-20 2021-01-05 汉诺威医学院 结合疱疹病毒抗原的嵌合抗原受体和car-t细胞
JPWO2020004337A1 (ja) * 2018-06-27 2021-08-02 国立大学法人東海国立大学機構 Cd37特異的キメラ抗原レセプター
WO2020011706A1 (en) 2018-07-09 2020-01-16 Oslo Universitetssykehus Hf Two chimeric antigen receptors specifically binding cd19 and igkappa
CN110832071A (zh) * 2018-09-14 2020-02-21 上海原能细胞医学技术有限公司 表面包含免疫调节剂的细胞及其用途
US20220031840A1 (en) * 2018-12-03 2022-02-03 Haemalogix Pty Ltd Method of Treatment
US20220175833A1 (en) * 2019-03-07 2022-06-09 Children's Medical Center Corporation Targeted delivery of immune-modulating vhh and vhh-fusion protein
AU2020283811A1 (en) * 2019-05-24 2021-12-16 Forty Seven, Inc. Regimes for co-administration of immunotherapeutic agents against c-kit and CD47
CN110305906B (zh) * 2019-07-18 2021-11-12 山东大学第二医院 一种靶向pdl1的car嵌合受体的慢病毒载体及pdl1-car-t细胞
WO2021113853A1 (en) * 2019-12-05 2021-06-10 Vycellix, Inc. Modulators of the immune escape mechanism for universal cell therapy
CA3176109A1 (en) * 2020-03-27 2021-09-30 Haemalogix Pty Ltd Composition and method
JP2023525007A (ja) 2020-05-04 2023-06-14 サリオジェン セラピューティクス インコーポレイテッド 転位に基づく療法
WO2021232200A1 (en) * 2020-05-18 2021-11-25 Guangdong Tcrcure Biopharma Technology Co., Ltd. Il-12 armored immune cell therapy and uses thereof
CN116635064A (zh) 2020-12-18 2023-08-22 世纪治疗股份有限公司 具有适应性受体特异性的嵌合抗原受体系统
WO2022268196A1 (zh) * 2021-06-25 2022-12-29 天辰生物医药(苏州)有限公司 靶向gpc3的抗原结合蛋白
US20240352481A1 (en) * 2021-07-29 2024-10-24 Vor Biopharma Inc. Nfat-responsive reporter systems for assessing chimeric antigen receptor activation and methods of making and using the same
KR102789265B1 (ko) * 2022-04-14 2025-04-02 주식회사 셀랩메드 키메릭 항원 수용체 및 hgf 결합 억제 물질의 조합 요법
WO2024196796A1 (en) * 2023-03-17 2024-09-26 Cartesian Therapeutics, Inc. Intracellular signaling and costimulatory domains adapted for prolonged expression of chimeric antigen receptors
WO2025136986A2 (en) 2023-12-18 2025-06-26 Genzyme Corporation Il-12 loss of potency muteins

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003004056A1 (en) * 2001-07-06 2003-01-16 Pacmab Pty Ltd Method for treating multiple myeloma
WO2010115238A1 (en) * 2009-04-07 2010-10-14 Immune System Therapeutics Ltd Method for treating immune disorders
WO2014190273A1 (en) * 2013-05-24 2014-11-27 Board Of Regents, The University Of Texas System Chimeric antigen receptor-targeting monoclonal antibodies
WO2015009740A2 (en) * 2013-07-15 2015-01-22 Cell Signaling Technology, Inc. Anti-mucin 1 binding agents and uses thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7888479B2 (en) 2002-11-27 2011-02-15 Biogen Idec Ma Inc. Humanized antibodies against monocyte chemotactric proteins
EP1909836A4 (en) * 2005-08-04 2009-10-14 Univ California METHODS OF TREATING AND DETECTING BETA CELL ASSOCIATED DISEASE
US20100330046A1 (en) * 2009-05-21 2010-12-30 Stratatech Corporation Human skin substitutes expressing il-12
ES2754394T3 (es) * 2010-09-08 2020-04-17 Chemotherapeutisches Forschungsinstitut Georg Speyer Haus Receptores de antígenos quiméricos con una región bisagra optimizada
US20140322216A1 (en) * 2011-11-08 2014-10-30 The Trustees Of The University Of Pennsylvania Glypican-3-specific antibody and uses thereof
CN105073133B (zh) * 2012-12-21 2021-04-20 Aveo制药公司 抗gdf15抗体
CN104177499B (zh) * 2013-05-27 2019-01-08 上海雅科生物科技有限公司 一种嵌合抗原受体、编码基因、表达载体及其应用
EP3134434A4 (en) * 2014-04-25 2017-10-25 Bluebird Bio, Inc. Kappa/lambda chimeric antigen receptors
PT3286223T (pt) 2015-04-23 2024-03-22 HaemaLogiX Ltd Recetores de antigénio quimérico do antigénio do mieloma kappa e suas utilizações

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003004056A1 (en) * 2001-07-06 2003-01-16 Pacmab Pty Ltd Method for treating multiple myeloma
WO2010115238A1 (en) * 2009-04-07 2010-10-14 Immune System Therapeutics Ltd Method for treating immune disorders
WO2014190273A1 (en) * 2013-05-24 2014-11-27 Board Of Regents, The University Of Texas System Chimeric antigen receptor-targeting monoclonal antibodies
WO2015009740A2 (en) * 2013-07-15 2015-01-22 Cell Signaling Technology, Inc. Anti-mucin 1 binding agents and uses thereof

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
HOMBACH AA, ABKEN H "Costimulation by chimeric antigen receptors revisited: the T cell antitumor response benefits from combined CD28-OX40 signalling", Int. J. Cancer, 2011, Vol. 129, pp. 2935-2944. *
HUSTON JS et. al. "Protein engineering of antibody binding sites: Recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichia coli", Proc. Natl. Acad. Sci. USA, 1988, Vol. 85, pp. 5879-5883. *
HUSTON JS et. al. "Protein engineering of antibody binding sites: Recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichia coli", Proc. Natl. Acad. Sci. USA, 1988, Vol. 85, pp. 5879-5883. БЕССМЕЛЬЦЕВ СС "Множественная миелома (патогенез, клиника, диагностика, дифференциальный диагноз)", Клиническая онкогематология, 2013, Т. 6, No. 3, стр. 237-267. *
VERA J et. al. "T lymphocytes redirected against the κ light chain of human immunoglobulin efficiently kill mature B lymphocyte-derived malignant cells", Blood, 2006, Vol. 108. No. 12, pp. 3890-3897. *
БЕССМЕЛЬЦЕВ СС "Множественная миелома (патогенез, клиника, диагностика, дифференциальный диагноз)", Клиническая онкогематология, 2013, Т. 6, No. 3, стр. 237-267. *

Also Published As

Publication number Publication date
AU2016253126B2 (en) 2020-01-30
WO2016172703A2 (en) 2016-10-27
DK3286223T5 (da) 2024-10-07
EP3286223B8 (en) 2024-04-03
KR20170139044A (ko) 2017-12-18
HRP20240415T1 (hr) 2025-05-23
KR102623427B1 (ko) 2024-01-12
HK1251586A1 (en) 2019-02-01
RU2017138528A3 (OSRAM) 2019-09-03
HK1252854A1 (zh) 2019-06-06
IL255207B2 (en) 2023-09-01
RU2017138528A (ru) 2019-05-07
CN107922489B (zh) 2022-02-25
AU2016253126A1 (en) 2017-10-12
CN107922489A (zh) 2018-04-17
EP3286223B1 (en) 2024-02-28
ES2976236T3 (es) 2024-07-29
BR112017022838A2 (pt) 2018-07-17
EP4368641A3 (en) 2024-08-14
EP3286223A4 (en) 2018-12-05
EP4368641A2 (en) 2024-05-15
PT3286223T (pt) 2024-03-22
HUE065799T2 (hu) 2024-06-28
US20180228892A1 (en) 2018-08-16
US11305011B2 (en) 2022-04-19
US20220193232A1 (en) 2022-06-23
CA2978964A1 (en) 2016-10-27
JP7229768B2 (ja) 2023-02-28
IL255207A0 (en) 2017-12-31
FI3286223T3 (fi) 2024-03-25
IL255207B1 (en) 2023-05-01
JP2018519356A (ja) 2018-07-19
JP2021073312A (ja) 2021-05-13
JP2023024793A (ja) 2023-02-16
EP3286223A2 (en) 2018-02-28
NZ735778A (en) 2024-03-22
WO2016172703A3 (en) 2016-11-24
DK3286223T3 (da) 2024-04-02

Similar Documents

Publication Publication Date Title
RU2743188C2 (ru) Химерные антигенные рецепторы к каппа-антигену миеломы и варианты их применения
AU2022200257B2 (en) Chimeric antigen receptors and methods of use thereof
US20240277765A1 (en) Chimeric receptors and methods of use thereof
CN113817061B (zh) 一种抗cld18a2单域抗体及其抗肿瘤用途
KR102627246B1 (ko) 길항작용 cd40 모노클로날 항체 및 그의 용도
CN107208047B (zh) 靶向b-细胞成熟抗原的嵌合抗原受体及其用途
Katz et al. Mouse mast cell gp49B1 contains two immunoreceptor tyrosine-based inhibition motifs and suppresses mast cell activation when coligated with the high-affinity Fc receptor for IgE.
CN109562126A (zh) 嵌合抗原受体(car)、组合物及其使用方法
RU2770002C2 (ru) Химерный антигенный рецептор
US20250136697A1 (en) Methods and compositions comprising b7h3 chimeric antigen receptors
CN110234343A (zh) 用于治疗癌症的经工程改造t细胞
EP3420000A1 (en) Modified cells for immunotherapy
US12479923B2 (en) Chimeric antigen receptors and related methods and compositions for the treatment of cancer
CN117143248A (zh) 靶向bcma-cd19的双特异性嵌合抗原受体及其应用
JP2023524811A (ja) Cd70特異的融合タンパク質を使用したtcrリプログラミングのための組成物及び方法
CN116249559A (zh) 抗独特型组合物及其使用方法
US20240189351A1 (en) Il-13ra2 chimeric antigen receptors and methods of use
WO2023155852A1 (zh) 经修饰的免疫效应细胞及其用途
HK40112160A (en) Kappa myeloma antigen chimeric antigen receptors and uses thereof
WO2024254450A1 (en) Improved endodomains and immune cells comprising the same
WO2026001894A1 (zh) 靶向axl的嵌合抗原受体及其用途
WO2023044304A1 (en) Chimeric adaptor and kinase signaling proteins and their use in immunotherapy
HK40067959A (en) Chimeric receptors and methods of use thereof
HK40010509A (en) Engineered t cells for the treatment of cancer
HK1251586B (en) Kappa myeloma antigen chimeric antigen receptors and uses thereof